{
  "schemaVersion": 2,
  "eyebrow": "Sleep Medicine",
  "title": "Restless Legs Syndrome",
  "summary": "Restless legs syndrome is a clinical sensorimotor diagnosis requiring exclusion of mimics, identification of iron deficiency and medication triggers, and treatment proportional to symptom burden. Iron replacement and alpha-2-delta ligands generally reduce reliance on dopaminergic therapy and its augmentation risk.",
  "seoDescription": "Physician guide to diagnosing restless legs syndrome, checking iron status, avoiding mimics and triggers, and selecting therapy while preventing augmentation.",
  "clinicalQuestion": "How should clinicians diagnose, evaluate, and treat restless legs syndrome while minimizing dopaminergic augmentation?",
  "specialty": "Sleep Medicine",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "restless legs syndrome",
    "Willis-Ekbom disease",
    "iron deficiency",
    "augmentation",
    "gabapentin",
    "dopamine agonists",
    "periodic limb movements"
  ],
  "keyTakeaways": [
    "Diagnose RLS clinically from an urge to move the legs, symptoms at rest, relief with movement, and evening or nighttime predominance; polysomnography is not required for the diagnosis. [16][19]",
    "Measure iron indices in clinically significant RLS and correct low iron stores; ferritin of 75 micrograms/L or lower is a treatment-selection threshold used in a recent PLM/RLS management algorithm. [8][15][24]",
    "For persistent troublesome RLS, alpha-2-delta ligands are favored over chronic dopaminergic therapy because dopamine agonists can cause augmentation and impulse-control disorders. [15][16][23]",
    "New earlier daytime onset, shorter latency at rest, escalating severity, or spread to arms or trunk during dopaminergic treatment indicates augmentation rather than simple disease progression. [16][23][24]",
    "Before escalating medication, correct iron deficiency and remove exacerbating drugs such as dopamine antagonists, selected antidepressants, and antihistamines when clinically feasible. [6][15]"
  ],
  "sections": [
    {
      "id": "clinical-diagnosis-and-mimics",
      "eyebrow": "Diagnosis",
      "heading": "Make the clinical diagnosis and exclude common mimics",
      "intro": "RLS is diagnosed clinically; the decisive task is separating the characteristic circadian movement-responsive syndrome from mimics.",
      "paragraphs": [
        "Confirm all core features in the history: an urge to move the legs, usually with uncomfortable sensations; onset or worsening during rest or inactivity; partial or complete relief with movement; and predominant evening or nighttime symptoms. RLS is a circadian sensorimotor disorder, and diagnosis is based on International Restless Legs Syndrome Study Group clinical criteria rather than polysomnography. [16][17]",
        "Ask the patient to describe what happens during immobility and what changes after walking or stretching. Nocturnal periodic limb movements support a coexisting sleep-related movement phenomenon but do not establish RLS; periodic limb movements in sleep occur in approximately 80% of patients with RLS. If sleep disruption, another sleep disorder, or periodic limb movement burden will change management, polysomnography can document sleep disturbance and limb movements. [7][19]",
        "Do not label involuntary nocturnal jerks as RLS without a conscious urge to move and movement-related relief. In Parkinson disease, distinguish RLS from periodic limb movements and diphasic dyskinesia before assigning treatment; these entities can overlap clinically but require different management. [8]"
      ],
      "bullets": [
        "Use the International Restless Legs Syndrome Study Group severity scale to quantify baseline burden and response: 1-10 mild, 11-20 moderate, 21-30 severe, and more than 30 very severe. [7]",
        "Reserve daily pharmacotherapy for symptoms occurring several times weekly that cause moderate-to-very-severe discomfort or functional impairment; consider intermittent treatment when symptoms are less frequent. [15][23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical distinctions that change the next diagnostic or treatment step. [8][16][19]",
        "columns": [
          "Pattern",
          "Discriminator",
          "Next step"
        ],
        "rows": [
          [
            "RLS",
            "Urge to move, worse at rest, relieved by movement, with evening/night predominance. [16]",
            "Obtain iron studies and review provoking medications; treat only if burden warrants therapy. [15][23]"
          ],
          [
            "Periodic limb movements",
            "Repetitive movements during sleep; may coexist with RLS but do not by themselves establish RLS. [7][19]",
            "Use polysomnography when documentation of sleep disturbance or limb movements will affect management. [19]"
          ],
          [
            "Dopaminergic augmentation",
            "Symptoms become more intense, start earlier in the day, occur after shorter inactivity, or spread to arms, trunk, or face. [16][23][24]",
            "Review iron status and extrinsic exacerbators; avoid further dopaminergic dose escalation as the default response. [15]"
          ],
          [
            "Parkinson disease motor fluctuation or dyskinesia",
            "Leg symptoms may overlap with RLS or PLM; diphasic dyskinesia is a key alternative diagnosis. [8]",
            "Establish the motor-phenomenology diagnosis before adjusting dopaminergic therapy. [8]"
          ]
        ]
      }
    },
    {
      "id": "initial-evaluation",
      "eyebrow": "Workup",
      "heading": "Evaluate iron status and reversible exacerbators first",
      "intro": "The highest-yield initial actions are iron assessment and medication reconciliation.",
      "paragraphs": [
        "Obtain serum ferritin as part of the baseline evaluation of clinically meaningful RLS. Low iron stores are a recognized treatment target, and a ferritin threshold of 75 micrograms/L or lower has been used to direct iron supplementation in an RLS/PLM treatment algorithm. [8][15][24]",
        "Medication reconciliation should specifically identify dopamine antagonists, selected antidepressants, and antihistamines, which can worsen RLS symptoms; assess alcohol, caffeine, and nicotine exposure as potentially modifiable aggravators. When a suspected medication is necessary, balance symptom burden against the indication for that agent rather than stopping it reflexively. [6][15]",
        "Check for renal impairment before prescribing gabapentin, gabapentin enacarbil, or pregabalin because reduced renal clearance can produce accumulation. In chronic renal insufficiency, begin at the lower end of dosing and titrate toward a lower target dose. [24]"
      ],
      "bullets": [
        "Use massage or temperate baths as nonpharmacologic options for patients with adequate control using these measures, rather than automatically initiating chronic medication. [24]",
        "Escalate the evaluation of sleep complaints with polysomnography when identifying nocturnal sleep disruption or periodic limb movements will alter treatment selection. [19]"
      ],
      "subsections": [],
      "table": {
        "caption": "Baseline evaluation linked to management decisions. [6][8][19][24]",
        "columns": [
          "Assessment",
          "Actionable finding",
          "Management consequence"
        ],
        "rows": [
          [
            "Serum ferritin",
            "Ferritin 75 micrograms/L or lower. [8]",
            "Use iron supplementation as part of first-line management; consider intravenous iron when oral iron is not tolerated or disease remains severe or refractory. [24]"
          ],
          [
            "Medication review",
            "Dopamine antagonist, selected antidepressant, or antihistamine exposure. [6][15]",
            "Remove, substitute, or minimize the exacerbating agent when clinically feasible. [6][15]"
          ],
          [
            "Renal function",
            "Chronic renal insufficiency. [24]",
            "Use lower starting doses and lower titration targets for alpha-2-delta ligands. [24]"
          ],
          [
            "Sleep study",
            "Need to document sleep disturbance or periodic limb movements. [19]",
            "Perform polysomnography selectively; do not use it as a prerequisite for clinical RLS diagnosis. [16][19]"
          ]
        ]
      }
    },
    {
      "id": "treatment-selection",
      "eyebrow": "Treatment",
      "heading": "Select therapy by symptom frequency, iron status, and augmentation risk",
      "intro": "Treat iron deficiency and avoid exposing patients with intermittent symptoms to unnecessary chronic drug risk.",
      "paragraphs": [
        "For low iron stores, use iron replacement as a first-line intervention. Oral iron is appropriate when tolerated; intravenous iron is an option for oral intolerance and for intense, severe, refractory symptoms or augmentation. Vitamin C improves oral iron absorption, while gastrointestinal upset, nausea, and constipation are common oral-iron limitations. [15][24]",
        "For troublesome persistent RLS requiring medication, select an alpha-2-delta ligand such as gabapentin, gabapentin enacarbil, or pregabalin when the goal is to avoid dopaminergic augmentation and impulse-control toxicity. Gabapentin enacarbil is FDA approved for RLS; gabapentin and pregabalin have demonstrated efficacy but are not identified as FDA-approved RLS therapies in the comparative review. [16][23]",
        "Counsel patients receiving alpha-2-delta ligands about sleepiness, dizziness, unsteadiness, possible driving impairment, and fall risk, particularly in older adults. Peripheral edema and weight gain may occur with gabapentin. Dose conservatively in renal impairment. [24]",
        "Dopamine agonists—pramipexole, ropinirole, and rotigotine—are effective and FDA approved for RLS, but reserve long-term use for situations in which anticipated benefit outweighs augmentation and impulse-control risk. Keep the dose as low as possible and do not exceed RLS-specific recommended doses. [15][16][23]",
        "Levodopa can relieve RLS but chronic use is frequently associated with augmentation. Opioids may be considered as an alternative in severe disease, particularly after dopamine agonist-related augmentation, while the evidence base for opioids and clonazepam is less sufficient for routine recommendation. [15][16]"
      ],
      "bullets": [
        "Use intermittent rather than daily pharmacotherapy when symptoms are mild or intermediate in frequency and do not produce substantial quality-of-life impairment. [15][23]",
        "In a patient with ferritin above 75 micrograms/L and clinically significant periodic limb movements in Parkinson disease, the cited algorithm proceeds to dopaminergic therapy; this disease-specific approach should not be generalized automatically to uncomplicated RLS. [8]"
      ],
      "subsections": [
        {
          "heading": "Medication selection at the point of care",
          "paragraphs": [
            "No source-supported dose schedule is available in the cited material for gabapentin, pregabalin, gabapentin enacarbil, pramipexole, ropinirole, rotigotine, levodopa, or opioids. Prescribe and titrate against current product labeling and disease-specific guidance, with early reassessment for sedation, falls, impulse-control behaviors, and augmentation. [15][16][23][24]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Treatment choice by clinical scenario and dominant tradeoff. [15][16][23][24]",
        "columns": [
          "Clinical scenario",
          "Preferred next step",
          "Key tradeoff or monitoring"
        ],
        "rows": [
          [
            "Ferritin 75 micrograms/L or lower",
            "Iron supplementation. [8][15]",
            "Oral iron can cause nausea, gastrointestinal upset, and constipation; vitamin C improves absorption. [24]"
          ],
          [
            "Frequent troublesome RLS without prior augmentation",
            "Consider gabapentin, gabapentin enacarbil, or pregabalin. [15][16][24]",
            "Monitor sedation, dizziness, unsteadiness, driving impairment, edema, weight gain, and renal accumulation. [24]"
          ],
          [
            "Dopaminergic therapy chosen",
            "Use the lowest effective RLS-specific dose. [15]",
            "Monitor for augmentation and impulse-control disorders; impulse-control disorders may occur in up to 9%-17% of treated patients. [23]"
          ],
          [
            "Severe refractory RLS or oral-iron intolerance",
            "Consider intravenous iron. [24]",
            "Use as an escalation strategy rather than bypassing evaluation of iron status and exacerbating medications. [15][24]"
          ],
          [
            "Dopamine agonist-related augmentation",
            "Correct iron and extrinsic triggers; consider transition away from dopaminergic reliance and opioid therapy in selected severe cases. [15][16]",
            "Avoid interpreting earlier or spreading symptoms as an indication for simple dose escalation. [15][23]"
          ]
        ]
      }
    },
    {
      "id": "augmentation-and-follow-up",
      "eyebrow": "Monitoring",
      "heading": "Recognize augmentation early and change the treatment trajectory",
      "intro": "Augmentation is a treatment complication that should trigger reassessment, not automatic dopaminergic escalation.",
      "paragraphs": [
        "At every follow-up after starting levodopa or a dopamine agonist, ask whether symptoms now begin earlier in the day, emerge more quickly with inactivity, have become more intense, or have spread beyond the legs. This cluster defines augmentation and differs from ordinary residual symptoms. [16][23][24]",
        "High dopaminergic dose is a modifiable augmentation risk factor. When augmentation emerges, first address low iron stores and extrinsic exacerbators, including antidepressants and antihistamines when appropriate; alpha-2-delta therapy and, in selected severe cases, opioids are alternatives to continued dopaminergic escalation. [15][18]",
        "Screen specifically for impulse-control behaviors during dopamine agonist therapy. Comparative evidence estimates impulse-control disorders in up to 9%-17% of patients with RLS receiving these drugs, making anticipatory counseling and active surveillance clinically necessary. [23]"
      ],
      "bullets": [
        "Reassess symptom timing, body distribution, frequency, sleep disruption, daytime function, adverse effects, and treatment adherence at medication follow-up. Earlier onset or anatomical spread should be recorded as potential augmentation. [16][23][24]",
        "Recheck iron status when symptoms worsen, augmentation appears, or iron replacement is being used as part of disease control. [15][18]"
      ],
      "subsections": [],
      "table": {
        "caption": "Follow-up findings that require a treatment change. [15][16][23][24]",
        "columns": [
          "Follow-up finding",
          "Interpretation",
          "Next action"
        ],
        "rows": [
          [
            "Earlier daily onset or shorter rest latency",
            "Possible dopaminergic augmentation. [16][23]",
            "Review dose, iron status, and exacerbating medications rather than simply increasing dopamine agonist exposure. [15][18]"
          ],
          [
            "Symptoms spread to arms, trunk, or face",
            "Augmentation phenotype. [23]",
            "Reassess dopaminergic regimen and consider non-dopaminergic alternatives. [15][16]"
          ],
          [
            "Sleepiness, dizziness, unsteadiness, or driving impairment on alpha-2-delta ligand",
            "Dose-related tolerability concern with fall and safety implications. [24]",
            "Reduce exposure or revise therapy; reassess renal function and concurrent sedating risks. [24]"
          ],
          [
            "New compulsive behaviors on dopamine agonist",
            "Impulse-control adverse effect. [23]",
            "Reassess the necessity of dopamine agonist therapy and transition strategy. [15][23]"
          ]
        ]
      }
    },
    {
      "id": "special-populations",
      "eyebrow": "Special Situations",
      "heading": "Apply age, renal function, and Parkinson disease context to treatment selection",
      "intro": "Treatment risk is modified by renal clearance, fall vulnerability, and competing movement-disorder diagnoses.",
      "paragraphs": [
        "In older adults, alpha-2-delta ligand selection requires explicit assessment of baseline gait stability, fall risk, and driving demands because sleepiness, dizziness, and unsteadiness are common adverse effects. Renal impairment increases exposure, so lower starting doses and lower targets are advised. [24]",
        "In children and adolescents, use pediatric RLS diagnostic criteria and pediatric-focused iron-treatment guidance rather than extrapolating adult pharmacotherapy strategies. Pediatric RLS criteria and an International Restless Legs Syndrome Study Group iron-treatment guideline are specifically cited in contemporary pediatric sleep medicine references. [11][13]",
        "For Parkinson disease with suspected nocturnal limb movements, first separate RLS, periodic limb movements, and diphasic dyskinesia. In the cited Parkinson disease algorithm, a periodic limb movement index of at least 15 prompts ferritin assessment, with ferritin 75 micrograms/L or lower directing iron plus dopaminergic therapy; this is a Parkinson disease-specific framework. [8]"
      ],
      "bullets": [],
      "subsections": [],
      "table": {
        "caption": "Context-specific precautions in RLS-related care. [8][11][13][24]",
        "columns": [
          "Population or context",
          "Decision point",
          "Practical implication"
        ],
        "rows": [
          [
            "Older adult",
            "High vulnerability to dizziness, unsteadiness, and falls with alpha-2-delta ligands. [24]",
            "Use conservative exposure and reassess gait and daytime sedation. [24]"
          ],
          [
            "Chronic renal insufficiency",
            "Reduced renal clearance can accumulate gabapentin-class drugs. [24]",
            "Start lower and titrate to a lower target. [24]"
          ],
          [
            "Child or adolescent",
            "Pediatric diagnostic and iron-treatment guidance is distinct. [11][13]",
            "Use pediatric criteria and pediatric sleep-medicine guidance before medication selection. [11][13]"
          ],
          [
            "Parkinson disease",
            "RLS, PLM, and diphasic dyskinesia can overlap. [8]",
            "Confirm phenotype before changing dopaminergic treatment. [8]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "When should polysomnography be ordered for suspected RLS?",
      "answer": "Do not require polysomnography to establish the clinical diagnosis. Order it selectively when documenting nocturnal sleep disturbance or periodic limb movements would change management or when another sleep disorder is under consideration. [16][19]"
    },
    {
      "question": "What finding most strongly suggests dopaminergic augmentation rather than undertreated RLS?",
      "answer": "Earlier symptom onset, shorter latency during inactivity, greater intensity, or spread from the legs to the arms, trunk, or face during dopaminergic therapy indicates augmentation. [16][23][24]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Medical Marketing in the United States, 1997-2016",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2720029",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 2,
      "title": "Metal Concentrations in Blood and Cerebrospinal Fluid of ...",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832017",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 3,
      "title": "Sleep Manifestations of Voltage-Gated Potassium Channel ...",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/1033014",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 4,
      "title": "February 2021 Issue of JAMA Network Open",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/issue/4/2",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 5,
      "title": "Supplementary appendix",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/cms/10.1016/S0140-6736(21)00218-X/attachment/04055c61-9dc5-416d-9929-d92b8f68df58/mmc2.pdf",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 6,
      "title": "Initiation and termination of dialysis in older patients with ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30060-X/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 7,
      "title": "Hepcidin and ferritin levels in restless legs syndrome: a case–control study | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-020-68851-0",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 8,
      "title": "Periodic limb movements in Parkinson's disease: a critical ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41531-026-01356-1",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 9,
      "title": "A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis | Communications Biology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42003-020-01575-z",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 10,
      "title": "Cobalamin and iron deficiency still presents a challenge in hereditary hemorrhagic telangiectasia | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-025-13911-6",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 11,
      "title": "Sleep-Wake Disorders in Childhood",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2020/08000/sleep_wake_disorders_in_childhood.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 12,
      "title": "Bupropion and Iron for Restless Leg Syndrome",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/annalsofian/fulltext/2017/20020/bupropion_and_iron_for_restless_leg_syndrome__do.23.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 13,
      "title": "Sleep Disorders in Childhood | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2023/08000/sleep_disorders_in_childhood.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 14,
      "title": "Insomnia",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2023/08000/insomnia.12.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 15,
      "title": "Restless legs syndrome: clinical presentation diagnosis and treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1389945715006474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 16,
      "title": "Treatment of Restless Legs Syndrome - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1878747923016483",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 17,
      "title": "Restless legs syndrome: clinical presentation diagnosis and treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1389945715006474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 18,
      "title": "Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1389945723004008",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 19,
      "title": "Restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.58.suppl_1.S87",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 20,
      "title": "Efficacy of pergolide in treatment of restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.WNL.0000124465.20878.84",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 21,
      "title": "Efficacy of cabergoline in restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.wnl.0000237742.08297.22",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 22,
      "title": "Effective cabergoline treatment in idiopathic restless legs ...",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.WNL.0000147297.51023.C8",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 23,
      "title": "Executive Summary - Treatment for Restless Legs Syndrome - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK115378",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Restless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116476",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Medical Marketing in the United States, 1997-2016",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2720029",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "by LM Schwartz · 2019 · Cited by 531 — ... Restless Legs Syndrome Study Group, Chronic Dry Eyes Workshop). To address possible industry bias, the National Academy of Medicine and the Guideline",
      "score": 0.21805303
    },
    {
      "number": 2,
      "title": "Metal Concentrations in Blood and Cerebrospinal Fluid of ...",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832017",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "by A Rakow · 2025 · Cited by 11 — Restless legs syndrome, 5 (2.5), 2 (1.0), 3 (1.5). Motor neurone disease, 11 (5.4), 3 (1.5), 8 (3.9). Amyotrophic lateral sclerosis, confirmed",
      "score": 0.16004303
    },
    {
      "number": 3,
      "title": "Sleep Manifestations of Voltage-Gated Potassium Channel ...",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/1033014",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "by JR Cornelius · 2011 · Cited by 141 — No new cases of restless legs syndrome were recognized. Periodic limb movement indices exceeding 15 per hour were recorded in 3 patients, all",
      "score": 0.13469648
    },
    {
      "number": 4,
      "title": "February 2021 Issue of JAMA Network Open",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/issue/4/2",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "This cohort study assesses whether bilateral oophorectomy for a benign indication prior to natural menopause is associated with risk of restless legs syndrome.",
      "score": 0.050018918
    },
    {
      "number": 5,
      "title": "Supplementary appendix",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/cms/10.1016/S0140-6736(21)00218-X/attachment/04055c61-9dc5-416d-9929-d92b8f68df58/mmc2.pdf",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "These reflect adverse effects of dopaminergic medication. f Mostly hyperhidrosis, Parkinson's disease and restless legs syndrome.",
      "score": 0.37559247
    },
    {
      "number": 6,
      "title": "Initiation and termination of dialysis in older patients with ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30060-X/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "by B Sprangers · 2021 · Cited by 9 — Restless legs • Avoid dopamine antagonists, some antidepressants, and opioids • Avoid alcohol, caffeine, and nicotine",
      "score": 0.19424585
    },
    {
      "number": 7,
      "title": "Hepcidin and ferritin levels in restless legs syndrome: a case–control study | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-020-68851-0",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Restless Legs Syndrome Study Group (IRLSSG) criteria (score ≤ 10: mild RLS; 11–20: moderate RLS; 21–30: severe RLS; and > 30: very severe RLS) as detailed elsewhere9.\"). RLS augmentation during the last two years before the study was diagnosed retrospectively according to published criteria16.\"). [.",
      "score": 0.7116118
    },
    {
      "number": 8,
      "title": "Periodic limb movements in Parkinson's disease: a critical ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41531-026-01356-1",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "To assist clinicians in the systematic management of PLM in PD patients, a clinical decision algorithm is proposed (Fig. 2). The algorithm initiates with a differential diagnosis to exclude RLS and diphasic dyskinesia, followed by treatment stratification based on PLMI values. For patients with a PL",
      "score": 0.666736
    },
    {
      "number": 9,
      "title": "A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis | Communications Biology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s42003-020-01575-z",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Ncontrols = 663,962; OR = 0.94 [0.93–0.96], P = 1.4 × 10−10) (Supplementary Data 14). We also generated polygenic risk scores (PRS) for ferritin and TSAT and regressed the scores against the same eleven clinical manifestations of iron overload and/or iron deficiency (Supplementary Data 15). The PRS ",
      "score": 0.5792344
    },
    {
      "number": 10,
      "title": "Cobalamin and iron deficiency still presents a challenge in hereditary hemorrhagic telangiectasia | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-025-13911-6",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Clinical relevance of cobalamin deficiency was assessed through a self-reported questionnaire. Even though only very few patients with HHT suffered from a true cobalamin deficiency (having been ruled out by analysis of holotranscobalamin and MMA), a large part of patients with cobalamin levels below",
      "score": 0.19571738
    },
    {
      "number": 11,
      "title": "Sleep-Wake Disorders in Childhood",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2020/08000/sleep_wake_disorders_in_childhood.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Crossref\n\nGoogle Scholar\n\n119.\n\nPicchietti DL, Bruni O, de Weerd A, et al. Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. _Sleep Med_ 2013;14(12):1253–1259.\n\nCrossref\n\nGoogle Scholar\n\n120.\n\nAllen RP, Picchietti DL, Auerbach M,",
      "score": 0.5849357
    },
    {
      "number": 12,
      "title": "Bupropion and Iron for Restless Leg Syndrome",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/annalsofian/fulltext/2017/20020/bupropion_and_iron_for_restless_leg_syndrome__do.23.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "by SK Praharaj · 2017 · Cited by 1 — The treatment of restless legs syndrome and periodic limb movement disorder in adults parameters with an evidence-based systematic review and meta-analyses: An",
      "score": 0.3420444
    },
    {
      "number": 13,
      "title": "Sleep Disorders in Childhood | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2023/08000/sleep_disorders_in_childhood.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Crossref\n\nGoogle Scholar\n\n96.\n\nWalters AS, Gabelia D, Frauscher B. Restless legs syndrome (Willis-Ekbom disease) and growing pains: are they the same thing? A side-by-side comparison of the diagnostic criteria for both and recommendations for future research. _Sleep Med_ 2013;14(12):1247–1252.\n\nCros",
      "score": 0.24868056
    },
    {
      "number": 14,
      "title": "Insomnia",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2023/08000/insomnia.12.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Crossref\n\nGoogle Scholar\n\n3.\n\nRiemann D, Benz F, Dressle RJ, et al. Insomnia disorder: state of the science and challenges for the future. _J Sleep Res_ 2022;31(4):e13604.\n\nCrossref\n\nGoogle Scholar\n\n4.\n\nMorgenthaler T, Owens J, Alessi C, et al. Practice parameters for behavioral treatment of bedtime",
      "score": 0.23197111
    },
    {
      "number": 15,
      "title": "Restless legs syndrome: clinical presentation diagnosis and treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1389945715006474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "## Abstract\n\nRestless legs syndrome (RLS) is a circadian disorder of sensory-motor integration that may be related to genetically determined dysregulation of iron transport across the blood-brain barrier. Dopamine agonists (DAs) have been considered the first-line therapy, but with the growing appre",
      "score": 0.72489023
    },
    {
      "number": 16,
      "title": "Treatment of Restless Legs Syndrome - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1878747923016483",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Treatment of Restless Legs Syndrome - ScienceDirect\n## Neurotherapeutics. Volume 11, Issue 1, January 2014, Pages 177-187. # Review Treatment of Restless Legs Syndrome. Author links open overlay panel. https://doi.org/10.1007/s13311-013-0247-9Get rights and content. Under an Elsevier user lic",
      "score": 0.7001783
    },
    {
      "number": 17,
      "title": "Restless legs syndrome: clinical presentation diagnosis and treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1389945715006474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Restless legs syndrome: clinical presentation diagnosis and treatment - ScienceDirect\n# Review Article Restless legs syndrome: clinical presentation diagnosis and treatment. Restless legs syndrome (RLS) is a circadian disorder of sensory-motor integration. Restless legs syndrome (RLS) is a ci",
      "score": 0.66045773
    },
    {
      "number": 18,
      "title": "Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1389945723004008",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Furthermore, the use of DAs in patients with RLS has been shown to improve their quality of life and sleep [7–9]. However, the long-term use of DAs may be associated with RLS augmentation caused by decreased serum ferritin levels . Despite this, these pharmacological agents constitute the mainstay t",
      "score": 0.7393665
    },
    {
      "number": 19,
      "title": "Restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.58.suppl_1.S87",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "Polysomnography (PSG) is useful to assess the nocturnal sleep disturbance and presence of periodic limb movements.",
      "score": 0.65940565
    },
    {
      "number": 20,
      "title": "Efficacy of pergolide in treatment of restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.WNL.0000124465.20878.84",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "Google Scholar\n\n2.\n\nMontplaisir JW, Boucher S, Nicolas A, et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of the restless leg syndrome. _Mov Disord_. 1998; _13_: 324–329.\n\nCrossref\n\nPubMed\n\nGoogle Scholar\n\n3.\n\nWalters AS, International Restless Legs Syndrome Study G",
      "score": 0.428784
    },
    {
      "number": 21,
      "title": "Efficacy of cabergoline in restless legs syndrome",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.wnl.0000237742.08297.22",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "Aug 23, 2006 — The primary efficacy measures were the periodic leg movements during sleep arousal index (PLMS-AI) and sleep efficiency. These and further PSG ...Read more",
      "score": 0.22316575
    },
    {
      "number": 22,
      "title": "Effective cabergoline treatment in idiopathic restless legs ...",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/01.WNL.0000147297.51023.C8",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "Objective: To assess the efficacy and safety of the dopamine agonist cabergoline (CAB) in patients with restless legs syndrome (RLS).",
      "score": 0.10092311
    },
    {
      "number": 23,
      "title": "Executive Summary - Treatment for Restless Legs Syndrome - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK115378",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Dopamine agonists can result in a treatment complication called augmentation, which is a drug-induced worsening of symptoms. Augmentation is characterized by greater symptom intensity, onset earlier in the day, and shorter latency during inactivity. With augmentation, symptoms may also spread to the",
      "score": 0.7906115
    },
    {
      "number": 24,
      "title": "Restless Legs Syndrome: Contemporary Diagnosis and Treatment - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116476",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Typical adverse effects of gabapentin, gabapentin enacarbil, and pregabalin include sleepiness, drowsiness, dizziness, and unsteadiness, so caution must be taken in elderly patients to avoid the risk of instability and falls. Driving impairment may occur. Providers also must use prudence with patien",
      "score": 0.7334523
    }
  ],
  "publishedAt": "2026-08-24T17:56:26.577713+00:00",
  "updatedAt": "2026-08-24T17:56:26.577713+00:00",
  "readingMinutes": 5,
  "slug": "restless-legs-syndrome"
}